Vemurafenib Delayed Progression in Metastatic, BRAF-Mutant CRC

January 23, 2017
Scott Kopetz, MD, PhD
Scott Kopetz, MD, PhD

This video covers results of the SWOG 1406 study, which tested the BRAF inhibitor vemurafenib in combination with irinotecan and cetuximab for patients with metastatic, BRAF-mutant colorectal cancer.

In this video, Scott Kopetz, MD, of the University of Texas MD Anderson Cancer Center in Houston, discusses results of the SWOG 1406 study, which tested the BRAF inhibitor vemurafenib in combination with irinotecan and cetuximab for patients with metastatic, BRAF-mutant colorectal cancer.

Dr. Kopetz presented results of the study (abstract 520) at the 2017 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, held January 19–21 in San Francisco.